ISRACANN BIOSCIENCES INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.015 CAD | -.--% |
|
-.--% | -.--% |
| 04-26 | Isracann Biosciences Inc. Announces Resignation of Directors | CI |
| 01-23 | Isracann Biosciences Inc. Announces Management Changes | CI |
Valuation
| Fiscal Period: May | 2020 | 2021 | 2022 |
|---|---|---|---|
| Capitalization 1 | 51.38 | 32.14 | 11.08 |
| Enterprise Value (EV) 1 | 47.49 | 30.18 | 10.87 |
| P/E ratio | -1.48 x | -1.21 x | -2.2 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -4.25 x | -6.32 x | -4.54 x |
| EV / FCF | 11,686,951 x | -13,172,842 x | -13,398,255 x |
| FCF Yield | 0% | -0% | -0% |
| Price to Book | 1.95 x | 8.16 x | 37.7 x |
| Nbr of stocks (in thousands) | 133,445 | 146,080 | 158,290 |
| Reference price 2 | 0.3850 | 0.2200 | 0.0700 |
| Announcement Date | 20-09-29 | 21-09-29 | 22-11-30 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: May | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Net sales | - | - | - | - |
| EBITDA 1 | -5.275 | -11.18 | -4.778 | -2.392 |
| EBIT 1 | -5.32 | -11.22 | -4.819 | -2.434 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -5.6 | -23.99 | -25.09 | -4.693 |
| Net income 1 | -9.904 | -24.2 | -25.16 | -4.693 |
| Net margin | - | - | - | - |
| EPS 2 | -0.2585 | -0.2609 | -0.1818 | -0.0318 |
| Free Cash Flow | - | 4.063 | -2.291 | -0.811 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 20-09-29 | 20-09-29 | 21-09-29 | 22-11-30 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: May | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | 4.18 | 3.89 | 1.96 | 0.21 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | 4.06 | -2.29 | -0.81 |
| ROE (net income / shareholders' equity) | - | -114% | -165% | -222% |
| ROA (Net income/ Total Assets) | - | -31.4% | -18.4% | -35.8% |
| Assets 1 | - | 77.02 | 136.5 | 13.1 |
| Book Value Per Share 2 | 0.4000 | 0.2000 | 0.0300 | 0 |
| Cash Flow per Share 2 | 0.1100 | 0.0300 | 0.0100 | 0 |
| Capex 1 | 0.2 | - | 0.01 | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 20-09-29 | 20-09-29 | 21-09-29 | 22-11-30 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 1.94M | |
| +45.15% | 6.34B | |
| -14.00% | 4.61B | |
| +9.54% | 3.39B | |
| -8.99% | 3.29B | |
| +50.03% | 2.02B | |
| -6.97% | 1.73B | |
| -0.31% | 1.67B | |
| +50.00% | 1.63B | |
| -10.61% | 1.59B |
- Stock Market
- Equities
- IPOT Stock
- Financials Isracann Biosciences Inc.